**RESEARCH ARTICLE**

**TGFβ1-transfected tendon stem cells promote tendon fibrosis**

Hong-Bin Yu*, Jing Xiong, Hui-Zhen Zhang, Qin Chen and Xu-Yong Xie

**Abstract**

**Background:** In aged people, tendon injuries frequently occur during sporting and daily activities. In clinical practice, typical physiotherapeutic, pharmacotherapeutic, and surgical techniques do not result in the full recovery of injured tendons, which may lead to chronic degenerative disease.

**Methods:** We first isolated tendon stem cells (TSCs) from rats and transfected them with the TGFβ1 gene, resulting in TGFβ1-TSCs. The proliferation of TSCs was detected using the Cell Counting Kit 8, and TSCs were identified by immunofluorescence analysis and differentiation capacity analysis. Aggrecan, COL2A1, alpha smooth muscle actin (α-SMA), and p-Smad2 expression levels were detected using western blotting and quantitative reverse transcription polymerase chain reaction. Additionally, a tendon injury model was generated to explore the effect of TGFβ1 on the repair of the tendon by TSCs.

**Results:** Compared with fibrinogen treatment, TSC + fibrinogen or TGFβ1-TSC + fibrinogen treatment significantly promoted the fibrosis of injured tendons, as evidenced by histological analyses, with TGFβ1-TSC + fibrinogen having a greater effect than TSC + fibrinogen. In TGFβ1-TSCs, increased expression levels of aggrecan and COL2A1 indicated that TGFβ1 signaling induced chondrogenic differentiation. Meanwhile, the increased collagen and α-SMA protein levels indicated that TGFβ1 promoted fibrogenesis. Additionally, TGFβ1 stimulated the production of phosphorylated Smad2 in TSCs, which suggested that the chondrogenic and fibrogenic differentiation of TSCs, as well as tissue regeneration, may be associated with the TGFβ1/Smad2 pathway.

**Conclusion:** TGFβ1-TSC therapy may be a candidate for effective tendon fibrosis.

**Keywords:** Tendon stem cells, TGFβ1, Osteogenesis, Chondrogenesis, Adipogenesis

**Introduction**

Aged people frequently experience tendon injuries while performing sports or even daily activities. Tendon injuries account for > 40% of musculoskeletal diseases [1, 2]. In clinical practice, physiotherapy, pharmacotherapy, and surgery are the typical choices for tendon repair [3–5]. However, these treatments do not usually result in a fully recovered tendon, which may result in a chronic degenerative disease [6]. During recovery in adults, injured tendons do not rebuild normal tissue, but mainly produce scar tissue, which lacks tensile strength [7]. The failure to completely recover is due to the low regeneration capability of tenocytes, which is associated with the hypovascularity and low metabolism of tendon tissue [8, 9]. Therefore, the development of new therapies capable of stimulating the regeneration of injured tendons has been encouraged in recent decades.

Uncommitted stem cells are endowed with a high proliferation potential; they can differentiate into all types of cells under the appropriate conditions [10]. Stem cell-based therapies have attracted increasing interest for tendon healing [11]. In contrast to adult tendons, fetal tendon tissue is capable of regeneration after...
impairment, and injured tendons fully regain their former performance [6]. However, embryonic stem cell-based therapies have a great risk of tumor generation, in addition to the ethical issues regarding the harvesting of cells from embryos [12]. Induced pluripotent stem cells are an alternative for tendon healing without ethical issues, but tumorigenesis cannot be avoided [13]. In recent years, mesenchymal stem cells have been shown to be safer because their self-renewal and/or differentiation potential are relatively restricted compared with those of embryonic and induced pluripotent stem cells [11]. Mesenchymal stem cells were first identified in tendon tissue in 2007 and were named tendon stem cells (TSCs) [14]. Several studies have shown that TSC-based therapies substantially promote tendon healing and tissue regeneration [15–17]. Stem cell-based treatment is the most promising therapeutic strategy for tendon healing [18, 19].

Previous studies have shown that tendon development and healing are highly associated with growth factors, such as fibroblast growth factor, epidermal growth factor, bone morphogenetic protein, and transforming growth factor (TGF) [11, 20]. Of these, TGFβ1 is one of the most attractive bioactive factors because it plays multiple roles in tendon healing [20]. Specifically, TGFβ1 is essential for tendon formation as it induces the expression of tendon-specific proteins and stimulates chondrogenic differentiation [21, 22]. TGFβ1 is also involved in the production of mesenchymal stem cells, it stimulates the production of collagen types I and III, and it participates in cell migration and mitogenesis [23, 24]. The application of stem cell-based therapies, in combination with growth factor supplementation, is being increasingly applied to tendon healing [11]. Nonetheless, information on the effects of TSC-based therapy in combination with TGFβ1 supplementation on tendon healing remains limited. Therefore, we isolated TSCs and overexpressed TGFβ1 in these cells to explore the effect of TGFβ1 on TSC-induced fibrogenesis and the expression of related molecules.

Methods

TSC isolation and culture

All animal experiments were approved by the animal research ethics committee of the First People's Hospital of Jiujiang City. TSCs were collected from male Sprague-Dawley rats weighing approximately 50 g. Prior to TSC collection, the rats were anesthetized by intraperitoneal injection of 0.03% pentobarbital sodium (30 mg/kg), and the tendons were separated from the paratendon, fat, and muscle tissues. The tendon samples were sectioned into 1 mm slices and digested in a 3 mg/mL collagenase solution (Sigma-Aldrich, St. Louis, MO, USA). The digested solution was filtered through a 70 μm cell strainer and centrifuged at 300 × g for 5 min to collect the tendon cells. The cells were cultured in Dulbecco's modified Eagle's medium (Gibco, Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Beyotime Biotechnology, Shanghai, China) and 1% penicillin-streptomycin antibiotic (Beyotime Biotechnology), and were sub-cultured after reaching 80% confluence.

Cell proliferation assay

Cells at passage three were seeded into 96-well plates (10^4 cells per well) and incubated with Cell Counting Kit-8 solution (Beyotime Biotechnology) according to the manufacturer's instructions. After 4 h, cell proliferation was assessed by measuring absorbance at 450 nm (SpectraMax; Molecular Devices, San Francisco, CA, USA).

Immunofluorescence analysis

Cells at passage three were incubated with fluorescein isothiocyanate-conjugated antibodies against surface markers, including anti-CD34 (Abcam, Cambridge, UK), anti-CD73 (BioLegend, San Diego, CA, USA), and anti-CD90 (BioLegend). Fluorescence was detected using a flow cytometer (NovoCyte 1300; ACEA, San Diego, CA, USA) to identify TSCs.

To detect collagen type I, TSCs were fixed with 4% paraformaldehyde (catalog number: P0099, Beyotime Biotechnology) and blocked with 20% heat-inactivated horse serum (Gibco) supplemented with 0.1% Triton-X 100 (Sigma-Aldrich). The cells were incubated with an anti-collagen type I antibody (catalog number: 14695-1-AP; Proteintech, Wuhan, China), followed by fluorescein-conjugated goat anti-rabbit IgG (catalog number: SA00003-11, Proteintech). The cells were then stained with 4′,6-diamidino-2-phenylindole (catalog number: P0131, Beyotime Biotechnology). Fluorescence was visualized under a fluorescence microscope (Leica, Wetzlar, Germany).

Differentiation capacity analysis

To evaluate multipotency, cells at passage three were sub-cultured into adipogenic, chondrogenic, or osteogenic media (Thermo Scientific, Pittsburgh, PA, USA). After 21 days of induction, the cells were fixed with 4% paraformaldehyde, washed with deionized water, and stained with alizarin red (osteogenic potential), alcian blue (chondrogenic potential), or oil red O (adipogenic potential). The stained cells were observed under a light microscope (Olympus, Tokyo, Japan).

Generation of a TSC line stably overexpressing TGFβ1

TGFβ1 cDNA was cloned and inserted into the pCDH-MCS-T2A-puro lentiviral vector (XIAMEN Anti-hela Biological Technology Trade Co. Ltd., Xiamen, China).
The following primers were used: TGFβ1 forward primer, 5'-TAGAGCTAGGAACTTGCCGACCCATGTGCCC GCCCTCAGGGGTGC-3' and TGFβ1 reverse primer, 5'-CAGCGGCACGGGATGCTGCGACTGGAGG AGCGCAC-3'. The TGFβ1 expression plasmid (pCDH-TGFβ1) or the pCDH-MCS-T2A-puro lentiviral vector (negative control) was transfected into HEK293T cells together with psPAX2 (a packaging plasmid) and pMD2.G (an envelope plasmid) using Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA). Cell supernatants containing lentivirus were harvested at 48 h post-transfection. Subsequently, the lentivirus was purified and concentrated and the median tissue culture infectious dose (TCID₅₀) of the lentivirus was determined, as previously described [25]. For stable transfection, TSCs were incubated with 10⁸ TCID₅₀/mL lentiviral particles to which 8 μg/mL polybrene had been added. At 3 days post-infection, the cells were treated with 1 mg/mL puromycin for 2 weeks. TGFβ1 overexpression was assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR), and the resulting cell line was named TGFβ1-TSCs.

Total RNA extraction and first-strand cDNA synthesis
Total RNA was isolated from TSCs using TRIzol reagent (Takara, Dalian, China), following the manufacturer’s instructions. RNA quality and quantity were determined using an agarose gel electrophoresis and spectrometry (Nanodrop 2000, Thermo Scientific), respectively. RNA samples were treated with DNase I and reverse transcribed with random primers, a dNTP mix, and M-MLV reverse transcriptase (Takara) to synthesize first-strand cDNA.

Quantitative PCR
qPCR was used to determine the expression levels of aggrecan, COL2A1, TGFβ1, and RNA18S5N (internal control). Reactions were performed on a QuantStudio 7 Flex (Thermo Scientific) using a SYBR Green PCR premix (Takara). The qPCR program was set as follows: a preheating step at 95 °C for 60 s; followed by 40 cycles of heating (95 °C for 30 s), annealing (58 °C for 35 s), and extension (72 °C for 60 s); and a final extension (72 °C for 10 min). Relative mRNA expression levels were determined using the 2⁻ΔΔCT method. The following primers were used for qPCR: TGFβ1 forward primer, 5' CACCGACCCCAATCTA-3'; TGFβ1 reverse primer, 5'-TGCTTCCCGAATGTCTGA-3'; COL2A1 forward primer, 5'-GGAAGAGGGGGAGACTCT-3'; COL2A1 reverse primer, 5'-TCCATGTTCGAAGAGACTC-3'; aggrecan forward primer, 5'-CTTCTGGCTTCGGAA TAG-3'; aggrecan reverse primer, 5'-CAGTGACATCCT CTACTC-3'; RNA18S5N forward primer, 5'-AGGCCGC GCAAATCCCAATCC-3'; and RNA18S5N reverse primer, 5'-GCCCTCACATTGTTACTGTG-3'.

Western blotting
TSCs were lysed with radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors (Beyotime Biotechnology). Isolated proteins were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, USA). After blocking with 5% skimmed milk, the membranes were incubated with antibodies against phosphorylated-smad2 (p-smad2) (catalog number: ab280888, Abcam), collagen type II (catalog number: ab34712, Abcam), aggrecan (catalog number: ab3778, Abcam), GAPDH (catalog number: 60004-1-Ig, Proteintech), or alpha smooth muscle actin (α-SMA) (catalog number: ab5694, Abcam), followed by incubation with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (catalog number: SA00001-1, Proteintech) or goat anti-rabbit IgG (catalog number: SA00001-2, Proteintech). The protein bands were visualized using an HRP chemiluminescence kit (Immuno-Star™, Bio-Rad) on an ImageQuant LAS 4000 system (GE Healthcare, Hino, Japan).

Surgical procedure and treatment
Adult male Sprague–Dawley rats weighing approximately 200 g were anesthetized by intraperitoneal injection of 0.03% pentobarbital sodium (30 mg/kg), and one-third of the patellar tendon was removed to mimic tendon injury following a well-established protocol [16, 26]. Fibrinogen, TSCs and fibrinogen (TGFβ1-TSCs and fibrinogen), or TGFβ1-TSCs and fibrinogen (TGFβ1-TSCs + fibrinogen), in combination with thrombin, were injected into the defect area. Four weeks after surgery, the rats were killed for histological examination.

Histological examination
Tendon samples were fixed with 4% paraformaldehyde for 24–48 h. The fixed samples were dehydrated, embedded in paraffin, and sectioned. The sections were stained with hematoxylin and eosin (H&E) and observed under a light microscope (BX51, Olympus).

Statistical analysis
Statistical analyses were performed using Graph Pad Prism 5.0 (San Diego, CA, USA). An independent Student’s t-test was used for comparisons between groups, and data normality was verified using the Shapiro-Wilk test. Statistical significance was set a p < 0.05.
Results

TSC identification

Cells obtained from rat tendons were large, flat, and fibroblastic (Fig. 1A) and cell proliferation increased from 0 to 72 h of culture (Fig. 1B). Subsequently, we detected the surface markers on the TSCs. The isolated cells were negative for the hematopoietic stem cell-like marker, CD34 (0.40%). However, they were positive for the mesenchymal stem cell-like markers, CD73 (99.51%) and CD90 (99.77%, Fig. 2A). In addition, the isolated cells were positive for collagen type I expression, indicating that they were derived from tendons (Fig. 2B). To confirm the identity of the isolated cells as TSCs, we performed differentiation experiments. Osteogenic differentiation was confirmed by the presence of calcium deposits and alkaline phosphatase activity using alizarin red staining. Chondrogenic and adipogenic differentiation were determined by the presence of sulfated glycosaminoglycan using alcian blue staining and the presence of oil droplets using oil red O staining (Fig. 3). These results showed

![Fig. 1](image1.png)  
**Fig. 1** Morphology and proliferation of tendon stem cells. A Morphological observation of isolated cells. B Cell proliferation was assessed using Cell Counting Kit-8.

![Fig. 2](image2.png)  
**Fig. 2** Expression of surface markers in tendon stem cells. A The expression of surface markers, including CD34, CD73, and CD90, was detected by flow cytometry. B The expression of collagen type I was detected by immunofluorescence. NC: cells did not incubate primary antibodies.
that the isolated cells could differentiate into osteoblasts, chondrocytes, and adipocytes, indicating that we had successfully isolated TSCs.

**TGFβ1 overexpression in TSCs increases the expression of chondrogenic and fibrogenic markers**

After the transfection of pCDH-TGFβ1, the expression of TGFβ1 was successfully detected in TSCs (Fig. 4A). The relative expression levels of the chondrogenic markers, aggrecan and COL2A1, in TSCs significantly increased upon TGFβ1 overexpression (Fig 4B). Furthermore, the protein levels of the fibrogenic and chondrogenic markers, collagen type II, α-SMA, p-smad2, and aggrecan significantly increased in TSCs upon TGFβ1 overexpression (Fig. 4C).

**TGFβ1 overexpression enhances TSC-mediated tendon fibrosis**

H&E staining showed that rupture and macrophage infiltration were still observed in tendons treated with
fibrinogen (Fig. 5). Macrophage infiltration was observed in TSCs + fibrinogen-treated tendons. In contrast, the tendons treated with TGFβ1-TSCs + fibrinogen were continuous, without macrophage infiltration. These findings suggest that TGFβ1 enhanced the tendon-fibrosis ability of TSCs.

**Discussion**

Tendon recovery was promoted by treatment with TSCs + fibrinogen or TGFβ1-TSCs + fibrinogen, both of which had a greater effect than treatment with fibrinogen alone. The observed improvement in tendon recovery confirmed that TSC-based therapies substantially promote tissue regeneration after injury, which is in agreement with previous findings [15–17]. Moreover, fibrosis was significantly higher in the TGFβ1-TSCs + fibrinogen group than in the TSCs + fibrinogen group. Our findings are consistent with those of a previous study of TSC-based therapies supplemented with exosomes or extracellular matrix containing TGFβ1 [27, 28]. These findings suggest that TGFβ1-TSC therapy may be a candidate for effective tendon healing. Furthermore, during the process of tissue injury healing, an appropriate amount of TGFβ1 promotes healing, whereas excessive TGFβ1 leads to scar hyperplasia and adverse effects on healing [29]. The amount of TGFβ1 produced by TGFβ1-TSCs was not determined, which is a limitation of this study. TGF-β1 signaling is regulated at multiple levels to avoid detrimental outcomes for cells [29]; thus, it is understandable that TGFβ1-TSCs promoted tendon repair, and this result indicates that the amount of TGFβ1 produced by TGFβ1-TSCs was appropriate.

Compared with TSCs, TGFβ1-TSCs showed higher expression levels of aggregan and COL2A1. The increased expression levels of these two chondrogenic markers indicated that TGFβ1 signaling promoted the differentiation of TSCs into the chondrogenic lineage [30]. Similarly, the protein levels of collagen type II and α-SMA were also increased in TSCs upon TGFβ1 overexpression, which indicated that TGFβ1 promoted fibrogenesis in TSCs [31]. The increased protein levels of collagen type II and α-SMA suggested the increased production of extracellular matrix components that are dedicated to tendon structure formation [32]. Additionally, p-Smad2 levels were increased by TGFβ1 in TSCs, indicating that chondrogenesis and fibrogenesis in TSCs were induced via the TGFβ1/Smad2 pathway [33, 34]. These findings suggest that the TGFβ1/Smad2 pathway induced chondrogenic and fibrogenic differentiation of TSCs and promoted tissue regeneration and tendon healing.

**Conclusions**

This study describes the molecular mechanism whereby TGFβ1 enhances the reparative effect of TSCs on tendons in vivo. Our results showed that TGFβ1 increased the levels of aggregan, COL2A1, α-SMA, and p-Smad2 in TSCs. Furthermore, we demonstrated that TGFβ1-TSCs have a positive effect on the fibrosis of damaged tendons.

**Acknowledgements**

Not applicable.

**Author contributions**

HBY was a major contributor in writing the manuscript. HBY, JX, HZZ, QC, and XYX performed experiments, analyzed data, and revised the manuscript. All authors read and approved the final manuscript.
Funding
This work was supported by the Natural Science Foundation of Jiangxi Province in China under grant number: 20202BAB206110.

Availability of data and materials
The data that support the findings of this study are available on request from the corresponding author.

Declarations

Ethics approval and consent to participate
The study was approved by the animal research ethics committee of the First People's Hospital of Jiuxiang City.

Consent for publication
Not applicable.

Competing interests
The authors have no competing interests to declare.

Received: 19 May 2022   Accepted: 29 June 2022

Published online: 21 July 2022

References

1. Lantto I, Heikkinen J, Flinkkilä T, Ohtonen P, Leppilahti J. Epidemiology of Achilles tendon ruptures: increasing incidence over a 33-year period. Scand J Med Sci Sports. 2015;25(1):e133-8.

2. Zhou B, Zhou Y, Tang K. An overview of structure, mechanical properties, and treatment for age-related tendinopathy. J Nutr Health Aging. 2014;18(4):441–8.

3. Mayor RB. Treatment of athletic tendinopathy. Conn Med. 2012;76(8):471–5.

4. Schwartz A, Watson JN, Hutchinson MR. Patellar tendinopathy. Sports health. 2015;7(5):415–20.

5. Coleman BD, Khan KM, Maffulli N, Cook JL, Wark JD. Studies of surgical outcome after patellar tendinopathy: clinical significance of methodological deficiencies and guidelines for future studies—Vice Kingston. J Orthop Tendon Study Group. Scand J Med Sci Sports. 2000;10(1):2–11.

6. Conrad S, Weber K, Walliser U, Geburek F, Skutella T. Stem cell therapy for tendon regeneration: current status and future directions. Adv Exp Med Biol. 2019;1084:611–93.

7. Howell K, Chien C, Bell R, Laudier D, Tufa SF, Keene DR, et al. Novel model of tendon regeneration reveals distinct cell mechanisms underlying regenerative and fibrotic tendon healing. Sci Rep. 2017;7:45238.

8. Nourissat G, Berenbaum F, Duprez D. Tendon injury: from biology to tendon repair. Nat Rev Rheumatol. 2015;11(4):223–33.

9. Docheva D, Müller SA, Majewski M, Evans CH. Biologics for tendon repair. Nat Rev Rheumatol. 2015;11(4):223–33.

10. Bell R, Taub P, Cagle P, Flatow EL, Andarawis-Puri N. Development of a mouse model of supraspinatus tendon insertion site healing. J Orthop Res Off Publ Orthop Res Soc. 2015;33(1):25–32.

11. Lui PP. (2015) Stem cell technology for tendon regeneration: current status, challenges, and future research directions. Stem Cells Cloning Adv Biol. 2019;1084:611–93.

12. Klein MB, Yalamanchi N, Pham H, Longaker MT, Chang J. Flexor tendon healing in vitro: effects of TGF-β on tendon cell collagen production. J Hand Surg. 2002;27(4):615–20.

13. Lui PP, Liu H, Liu Y, Huang L, Mu Y, Cai X, et al. DDX19A senses viral RNA and mediates NLRP3-dependent inflammasome activation. J Immunol (Baltim, Md: 1950). 2015;195(12):5732–49.

14. Zhang C, Zhang E, Yang L, Liu W, Lin J, Yuan C, et al. Histone deacetylase inhibitor treated cell sheet from mouse tendon stem/progenitor cells promotes tendon repair. Biomaterials. 2018;172:66–82.

15. Pan CCM, Huang S, Tang BCM, Rothrauff BB, et al. Tendon-derived extracellular matrix induces mesenchymal stem cell tenogenesis via an integrin/transforming growth factor-β crosstalk-mediated mechanism. J Biol Chem. 2018;293:122293.

16. Li M, Liu C, Li W, Jiang B, Guo Z, et al. Exosomes derived from tendon stem cells promote cell proliferation and migration through the TGF-β signal pathway. Biochem Biophys Res Commun. 2021;536:88–94.

17. Zhang L, Sheppard D, Chapman HA. TGF-β1 signalling and tissue fibrosis. Cold Spring Harbor Perspect Biol. 2018;10(4):a022293.

18. Rui YF, Lui PP, Li G, Fu SC, Lee WH, Chan KM. Isolation and characterization of multipotent rat tendon-derivated cells. Tissue Eng Part A. 2017;23:4633–43.

19. Wu Q, Zhou C, Liao NC, Ma L. Pro-osteogenic effects of fibrin glue in treatment of avascular necrosis of the femoral head in vivo by hepatocyte growth factor-transgenic mesenchymal stem cells. J Transl Med. 2014;12:114.

20. Xu J, Yu TT, Zhang K, Li M, Shi HJ, Meng XJ, et al. HGF alleviates renal interstitial fibrosis via inhibiting the TGF-β1/SMAD pathway. Eur Rev Med Pharmacol Sci. 2018;22(22):7621–7.

21. Lorda-Diez CI, Montero JA, Martinez-Cue C, Garcia-Porrero JA, Hurle JM. Transforming growth factors beta coordinate cartilage and tendon differentiation in the developing limb mesenchyme. J Biol Chem. 2009;284(43):29988–96.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.